Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia

By Lagacé-Wiens Philippe RS  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 789-799

Informa Healthcare

Access to resources Recommend Favorite

Ceftobiprole medocaril is noninferior to combination therapy with ceftazidime and linezolid for nosocomial pneumonia

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

STRAUSS composes key note for ceftobiprole medocaril in cSSSIs

By  

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859

By Qiu Y.   Bhattacharjee S.   Kraft P.   John T.M.   Craig E.   Haynes-Johnson D.   Guan J.   Jiang W.   Macielag M.   Sui Z.   Clancy J.   Lundeen S.  

European Journal of Pharmacology, Vol. 472, Iss. 1, 2003-07 ,pp. : 73-80

Elsevier

Access to resources Recommend Favorite

Growth Suppression and Mitotic Defect Induced by JNJ-7706621, an Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases

By  

Current Cancer Drug Targets, Vol. 12, Iss. 6, 2012-07 ,pp. : 625-639

Bentham Science Publishers

Access to resources Recommend Favorite